Inactive Instrument

News Abpro Corporation Nasdaq

Stocks

US0008501076

Biotechnology & Medical Research

All News

08-14	Abpro Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-20	Abpro Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Abpro Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-24	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index	CI
02-19	Abpro Holdings, Inc.(OTCPK:ABPO) dropped from NASDAQ Composite Index	CI
02-03	Abpro Holdings, Inc. Announces Board and Committee Resignations	CI
01-23	Abpro Holdings, Inc. Announces Board and Committee Changes	CI
01-16	Abpro Holdings, Inc. announced that it expects to receive $0.147 million in funding	CI
01-15	Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference	AQ
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
01-06	Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	AQ
01-06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
12-15	Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers	RE
12-15	Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers	AQ
12-15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
12-09	Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives	AQ
11-14	Abpro Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Abpro Holdings files prospectus related to the offer and resale of up to 9.78 million shares of common stock - SEC filing	RE
11-04	Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager	AQ
11-03	Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025	GL
25-10-22	Abpro Holdings Inc - to effect one-for-thirty reverse stock split - SEC filing	RE
25-10-02	Abpro Holdings, Inc. Announces Termination of Robert J. Markelewicz as Chief Medical Officer, Effective November 30, 2025	CI
25-08-13	Abpro Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-15	Abpro Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI